Fig. 7
Basal breast tumors are predicted to be more sensitive to bleomycin than luminal A, luminal B or Her2-positive breast tumors and the sensitivity is inversely correlated with ACE expression. a, Predicted bleomycin sensitivity for the five subtypes of TCGA BRCA samples: violin plots of the predicted ln (IC50) values of bleomycin for the five subtypes of breast tumors based on gene expression data and PAM50 classification of TCGA BRCA samples. b, ACE gene expression in cancer cell lines versus sensitivity to bleomycin: ACE expression in the CCLE cancer cell lines was positively correlated with observed ln (IC50) values for bleomycin (ρs = 0.27, p-value = 6.6E-11). The red line is the least-squares regression line. c, TCGA breast cancer tumor gene expression data: violin plots of ACE expression in TCGA basal-like, Her2-positive, luminal A, luminal B, and normal-like breast tumor samples. * p < 0.05; ** p < 0.005; **** p < 10− 6. Wilcoxon rank-sum test, two-sided